Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kelly Mousa"'
Autor:
Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David J. Propper
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment fo
Externí odkaz:
https://doaj.org/article/7c7d3ad82a9e4375ae3a8da492b9ac27
Autor:
Cristina Suárez, James M.G. Larkin, Poulam Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Bernadett Szabados, Kelly Mousa, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:2493-2502
PURPOSE Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibition i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::351c4ccc25cb02c3511c8c5e1d7c2e3d
https://doi.org/10.1200/jco.22.01414
https://doi.org/10.1200/jco.22.01414
Autor:
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
Publikováno v:
European urology
[Background] Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC).
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52be113364becd0e44b3fcaf865708b0
https://doi.org/10.1016/j.eururo.2022.04.013
https://doi.org/10.1016/j.eururo.2022.04.013
Autor:
Myria Nikolaou, Timothy J. Perren, Gia Nemsadze, Richard D. Baird, Robert McEwen, Daniel Stetson, Duncan Wheatley, A.M. Brunt, Hayley Cartwright, Max McLaughlin-Callan, Jean-Marc Ferrero, Peter Schmid, Cheryl Lawrence, Jacinta Abraham, Nicholas C. Turner, László Mangel, Melissa Phillips, Matthew Burgess, Peter Hall, John Conibear, Andrew Foxley, Aaron Prendergast, Kelly Mousa, Robert Stein, Yeon Hee Park, Javier Cortes, Stephen Chan, Elza C. de Bruin, Brian Dougherty
Publikováno v:
Cancer Research. 81:PD1-11
Background: In the PAKT study, addition of the oral AKT inhibitor capivasertib to 1st-line paclitaxel therapy for metastatic TNBC resulted in significantly longer progression-free survival (PFS; primary endpoint; Schmid, J Clin Oncol 2020). The strat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a130894bef5287d61428650111815a23
https://doi.org/10.1158/1538-7445.sabcs20-pd1-11
https://doi.org/10.1158/1538-7445.sabcs20-pd1-11
Autor:
Javier Cortes, Seock-Ah Im, Sherko Kuemmel, Melissa Phillips, Dieter Peeters, Peter Schmid, Patricia Marosics, Duncan Wheatley, Andreas Schneeweiss, Peter A. van Dam, Oliver Hoffmann, Sung-Bae Kim, Akhila Wimalasingham, Aaron Prendergast, Mark M. Kockx, Esther Zamora, Kelly Mousa, Yannick Waumans, Jens Uwe Blohmer
Publikováno v:
Cancer Research. 81:PD14-06
Background: Whilst Atezolizumab + nab-paclitaxel is the new standard of care in patients with PD-L1+ metastatic triple negative breast cancer (BC), the role of immunotherapy in ER+ BC has yet to be defined. ECLIPSE, an open label, phase II trial, aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d7146a86fdcadd4da4fd13a2c23d405
https://doi.org/10.1158/1538-7445.sabcs20-pd14-06
https://doi.org/10.1158/1538-7445.sabcs20-pd14-06
Autor:
Duncan Wheatley, A. Thompson, Steven Gendreau, Sirwan Hadad, Louise Lim, Lackner, C Zummit, Arnie Purushotham, Nigel J Bundred, Paul N. Mainwaring, Darren Korbie, A Shia, Kelly Mousa, Carol L. O'brien, Robert G. Price, E.J. Macaskill, Peter Schmid, Jennifer J. Hu, Matt Trau, S. Pinder, S-J Sarker, Patrycja Gazinska, Timothy R. Wilson
Publikováno v:
Cancer Research. 79:P2-08
Background: Although preclinical data suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance, results from randomized clinical trials have failed to identify a subgroup of patients that derive a substantial benefit. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55dd479777d5179b61252da2d2615618
https://doi.org/10.1158/1538-7445.sabcs18-p2-08-02
https://doi.org/10.1158/1538-7445.sabcs18-p2-08-02
Autor:
Thomas Powles, Maria Jose Mendez-Vidal, Alejo Rodriguez-Vida, Begoña Pérez-Valderrama, Emilio Esteban, Fiona Thistlethwaite, Poulam M. Patel, Urbano Anido Herranz, Gopalakrishnan Srinivasan, Abdel Hamid, James Larkin, Christy Ralph, Stefan N. Symeonides, Javier Puente, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Kelly Mousa, Cristina Suarez
Publikováno v:
Journal of Clinical Oncology. 40:LBA4503-LBA4503
LBA4503 Background: New drug combinations are required in advanced clear cell renal cancer (RCC). These potentially include MET inhibition with savolitinib (S) or CTLA-4 inhibition with tremelimumab (T). In this study these agents were given alone or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce727b677c11802fa26ac14ee1b0529c
https://doi.org/10.1200/jco.2022.40.17_suppl.lba4503
https://doi.org/10.1200/jco.2022.40.17_suppl.lba4503
Autor:
S. Kuemmel, Duncan Wheatley, Begoña Bermejo, F. Neus, Christian Schem, G. Viale, Agostina Stradella, J. Cortés, A. Llombart Cussac, Peter Schmid, F.J. Salvador Bofill, Aaron Prendergast, Esther Zamora, M. Phillips, Kelly Mousa, A. Anton Torres, Vanesa Quiroga, A. Cortes Salgado, O Gluz, M Melé
Publikováno v:
Annals of Oncology. 32:S411-S412
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c511d98f7967bf5d7de34eb1286983b
https://doi.org/10.1016/j.annonc.2021.08.404
https://doi.org/10.1016/j.annonc.2021.08.404
Autor:
Peter Schmid, S. Ledwidge, Arnie Purushotham, S Kümmel, N. Viehstädt, Charlotte Ackerman, Petra Krabisch, Duncan Wheatley, A. Thompson, P. Roy, E.J. Macaskill, Aaron Prendergast, Andrea Stefek, Marc Thill, O Gluz, Lee W. Jones, Kelly Mousa, P. Gomez-Pardo, G. Viale, J. Cortés
Publikováno v:
Annals of Oncology. 32:S449-S450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2b944aa333ac97b8027c2ec441200e5
https://doi.org/10.1016/j.annonc.2021.08.490
https://doi.org/10.1016/j.annonc.2021.08.490
Autor:
Mark Linch, Bernadett Szabados, Ignacio Duran, Thomas Powles, Denis Maillet, Michiel S. van der Heijden, Simon J. Crabb, Charlotte Tyson, Daniel Castellano, M.J. Méndez-Vidal, Urbano Anido Herranz, Alejo Rodriguez-Vida, Alain Ravaud, Andrew Protheroe, Aaron Prendergast, Gwenaelle Gravis, Cristina Suarez, Albert Font Pous, Kelly Mousa
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Urology Oncology
European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩
instname
European Urology Oncology
European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩
[Background] There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).
[Objective] To
[Objective] To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cf517da8426e48ffdf95300d13f191f
http://hdl.handle.net/10261/265965
http://hdl.handle.net/10261/265965
